X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12) 12
humans (9) 9
middle aged (8) 8
aged (7) 7
female (7) 7
male (7) 7
aged, 80 and over (5) 5
multidisciplinary sciences (5) 5
tuberculosis (5) 5
adult (4) 4
therapy (4) 4
treatment outcome (4) 4
article (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
chemotherapy (3) 3
disease-free survival (3) 3
infection (3) 3
infectious diseases (3) 3
kaplan-meier estimate (3) 3
lung diseases (3) 3
lung neoplasms - drug therapy (3) 3
lung neoplasms - mortality (3) 3
mycobacterium-tuberculosis (3) 3
1st-line treatment (2) 2
abridged index medicus (2) 2
active tuberculosis (2) 2
analysis (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
antitubercular agents - administration & dosage (2) 2
bacilli (2) 2
bacterial infections and mycoses (2) 2
body mass index (2) 2
cancer (2) 2
carboplatin - administration & dosage (2) 2
carboplatin-paclitaxel (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
cell death (2) 2
cisplatin - administration & dosage (2) 2
disease (2) 2
drug administration schedule (2) 2
gefitinib (2) 2
genetic predisposition to disease (2) 2
hematology, oncology and palliative medicine (2) 2
hemodialysis (2) 2
high prevalence (2) 2
in-tube assay (2) 2
infectious disease (2) 2
inflammation (2) 2
internal medicine (2) 2
latent tuberculosis infection (2) 2
leukocytes (2) 2
lung cancer (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - pathology (2) 2
lymphocytes (2) 2
macrophages (2) 2
medical colleges (2) 2
microbiology (2) 2
monocytes (2) 2
mutation (2) 2
mycobacterium tuberculosis (2) 2
nontuberculous mycobacteria (2) 2
oncology (2) 2
open-label (2) 2
patients (2) 2
peripheral blood mononuclear cells (2) 2
prospective studies (2) 2
quantiferon-tb-gold (2) 2
quinazolines - administration & dosage (2) 2
retrospective studies (2) 2
skin-test (2) 2
stage renal-disease (2) 2
survival analysis (2) 2
taiwan (2) 2
tumor necrosis factor-α (2) 2
young adult (2) 2
activation (1) 1
adenocarcinoma (1) 1
adherence (1) 1
administration, intravenous (1) 1
administration, oral (1) 1
adolescent (1) 1
age (1) 1
age distribution (1) 1
albumin (1) 1
animals (1) 1
anti-tuberculous treatment (1) 1
antibodies (1) 1
antigens, nuclear - genetics (1) 1
antigens, nuclear - immunology (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antituberculosis chemotherapy (1) 1
apnea (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10072, pp. 917 - 929
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
by Wu, MF and Shu, CC and Wang, JY and Yan, BS and Lai, HC and Chiang, BL and Wu, LSH and Yu, CJ
SCIENTIFIC REPORTS, ISSN 2045-2322, 08/2019, Volume 9, Issue 1, pp. 12534 - 10
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 02/2017, Volume 195, Issue 3, pp. 369 - 382
Rationale: How host genetic factors affect Mycobacterium tuberculosis (Mtb) infection outcomes remains largely unknown. SP110b, an IFN-induced nuclear protein,... 
Inflammation | Nuclear factor-kB | Tumor necrosis factor-a | Mycobacterium tuberculosis | Cell death | MYCOBACTERIUM-TUBERCULOSIS | TRANSCRIPTIONAL ACTIVATION | cell death | INDUCED APOPTOSIS | nuclear factor-kappa B | CELL-DEATH | NUCLEAR-BODY | tumor necrosis factor-alpha | TUMOR-NECROSIS-FACTOR | INTERFERON-GAMMA | inflammation | RESPIRATORY SYSTEM | PULMONARY TUBERCULOSIS | NF-KAPPA-B | INNATE IMMUNITY | CRITICAL CARE MEDICINE | Humans | Tumor Necrosis Factor-alpha - genetics | Immunity, Innate - genetics | Mycobacterium tuberculosis - immunology | NF-kappa B - immunology | Apoptosis - genetics | Autoantigens - genetics | Microarray Analysis | Minor Histocompatibility Antigens - genetics | Tumor Necrosis Factor-alpha - immunology | Nuclear Proteins - genetics | Minor Histocompatibility Antigens - immunology | Disease Models, Animal | Genetic Predisposition to Disease | Gene Expression Regulation - immunology | Nuclear Proteins - immunology | Tuberculosis - immunology | Animals | Antigens, Nuclear - genetics | Apoptosis - immunology | NF-kappa B - genetics | Tuberculosis - genetics | Autoantigens - immunology | Epistasis, Genetic - immunology | Mice | Polymorphism, Single Nucleotide | Antigens, Nuclear - immunology | Mycobacterium tuberculosis - genetics | nuclear factor-κB | Original | tumor necrosis factor-α
Journal Article
Scientific Reports, ISSN 2045-2322, 10/2016, Volume 6, Issue 1, p. 34577
The interferon-gamma release assay (IGRA) is useful for diagnosing latent tuberculosis infection (LTBI), however the rate of negative conversion is high,... 
MYCOBACTERIUM-TUBERCULOSIS | UNITED-STATES | QUANTIFERON-TB-GOLD | IN-TUBE ASSAY | ACTIVE TUBERCULOSIS | MULTIDISCIPLINARY SCIENCES | LATENT TUBERCULOSIS INFECTION | SKIN-TEST | HEMODIALYSIS | HIGH PREVALENCE | STAGE RENAL-DISEASE | Myeloid cells | Inflammation | Tuberculosis | Health risk assessment | Hemodialysis | Smoking
Journal Article
Respiration, ISSN 0025-7931, 08/2012, Volume 84, Issue 2, pp. 176 - 176
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.